Furthermore, M7S in combination with immune checkpoint inhibitors, specifically anti‐PD‐L1, led to more robust tumor suppression in syngeneic melanoma models than the combination with IL‐24 (Pradhan et al. 2022). The gene discussed is IL24; the disease is neoplasm.